Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29497059 | 1.00 | PRMT5 (0.44) | PRMT5WDR77CHRM3NAMPTUSP30 | |
| SCHEMBL22290386 | 0.86 | USP30 (0.46) | PRMT5WDR77CHRM3NAMPTUSP30 | |
| SCHEMBL25295010 | 0.85 | PRMT5 (0.44) | PRMT5WDR77NAMPTBACE1BACE2 | |
| SCHEMBL9938446 | 0.85 | PRMT5 (0.51) | PRMT5WDR77NAMPTUSP30JAK2 | |
| SCHEMBL30334881 | 0.84 | MGLL (0.50) | CHRM3TACR1RORC | |
| SCHEMBL24168673 | 0.84 | MGLL (0.50) | CHRM3TACR1RORC | |
| SCHEMBL25257331 | 0.82 | NAAA (0.44) | CHRM3IDO1TACR1 | |
| SCHEMBL25297006 | 0.81 | PRMT5 (0.41) | PRMT5WDR77CHRM3NAMPTUSP30 | |
| SCHEMBL29496997 | 0.81 | PRMT5 (0.41) | PRMT5WDR77CHRM3NAMPTUSP30 | |
| SCHEMBL25259842 | 0.80 | GPR119 (0.41) | PRMT5WDR77CHRM3BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | PRMT5 949/4885WDR77 3761/4885CHRM3 1040/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | PRMT5 949/4885WDR77 3761/4885CHRM3 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.